Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (50709)	1/31/2019 12:58:28 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

Regards the PEG-FGF21 and this P2b ( clinicaltrials.gov ), If someone know regime/doses I would like to hear about?

To: Miljenko Zuanic who wrote (50709)	1/31/2019 1:33:32 PM
From: atticus4paws	Read Replies (1) \| Respond to of 52153

Thanks Miljenko. 10 mg pegbelfermin daily (-6·8% vs -1·3%; p=0·0004) and in the group receiving 20 mg pegbelfermin weekly (-5·2% vs -1·3%; p=0·008) That's the part that caught my eye from the BMY study results. Vastly smaller result than VKTX, for example, at 12 weeks (the BMY study was 16 weeks).